The gonadotropin-releasing hormone agonist leuprolide acetate induces apoptosis and suppresses cell proliferative activity in rectovaginal endometriosis.
A gonadotropin-releasing hormone agonist, leuprolide acetate, was administered every 4 weeks for treatment of rectovaginal endometriosis. Degrees of apoptosis (percentage of in situ deoxyribonucleic acid 3'-end-labeled cells) and cell proliferative activity (percentage of cells with immunostaining for proliferating cell protein Ki-67) were examined in endometriotic glands of biopsy specimens taken before and during gonadotropin-releasing hormone agonist therapy. Gonadotropin-releasing hormone agonist induced apoptosis and suppressed cell proliferative activity in endometriotic glands.
Mizutani
T
T
Department of Obstetrics, Osaka Medical Center, Japan.
Sugihara
A
A
Nakamuro
K
K
Suehara
N
N
Terada
N
N
D000328:Adult; D017209:Apoptosis; D001706:Biopsy; D002455:Cell Division; D004715:Endometriosis / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D012002:Rectal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D014623:Vaginal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
D019394:Ki-67 Antigen; D016729:Leuprolide